please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech reported FY25 standalone revenue from operations of Rs. 4,661.25 lakhs (vs Rs. 4,488.05 lakhs in FY24), a modest ~4% growth. However, net profit after tax surged sharply to Rs. 757.07 lakhs from Rs. 252.22 lakhs (up ~200%), with EPS rising to Rs. 4.95 from Rs. 1.69. The big jump in profits was largely helped by Rs. 461.50 lakhs of one-time profit from the sale of property, plant and equipment booked under 'Other Income'. Q4 standalone revenue grew to Rs. 1,229.01 lakhs and PAT came in at Rs. 118.58 lakhs vs Rs. 69.77 lakhs a year ago. Consolidated FY25 PAT was Rs. 728.26 lakhs vs Rs. 252.62 lakhs. The company also reduced both long-term and short-term borrowings during the year and allotted shares under ESOPs and on warrant conversion. The auditor (P. Murali & Co.) issued an unmodified opinion but flagged an Emphasis of Matter on delayed/undisputed statutory dues of roughly Rs. 337.63 lakhs (PF, ESI, Professional Tax, TDS, and Self-Assessment Tax).
Headline PAT nearly tripled, but the gain is largely driven by a one-time PPE sale, so core operating improvement is more modest. The emphasis-of-matter on unpaid statutory dues is a governance red flag that investors should watch. Net debt reduction and equity infusion are positive for the balance sheet.